RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Human Metabolome Technologies Stock

Human Metabolome Technologies Employees 2024

Human Metabolome Technologies Employees

73

Ticker

6090.T

ISIN

JP3794530000

In 2024, Human Metabolome Technologies employed 73 people, a 0% change from the 73 number of employees in the previous year.

Human Metabolome Technologies Aktienanalyse

What does Human Metabolome Technologies do?

Human Metabolome Technologies Inc (HMT) is a Japanese company specializing in the research and development of metabolome analysis. HMT was founded in 2000 with the vision of gaining a deeper understanding of the metabolic processes of the human body in order to contribute to better healthcare. HMT's business model involves conducting metabolome analysis using mass spectrometry and other technologies to characterize the body's metabolic processes. This includes analyzing both healthy and diseased metabolism from samples such as blood, urine, or tissue in large numbers to identify biomarkers or signatures that can be used in the early detection, diagnosis, prognosis, and treatment of diseases. In this sense, HMT serves as an important partner for researchers in the pharmaceutical and biomedical industry who want to develop new diagnostic and therapeutic approaches. In recent years, HMT has developed a wide range of metabolome analysis technologies tailored to various applications. One of HMT's most important products is the Targeted Metabolomics Platform, which allows for the quantification of a variety of metabolites in samples such as blood or urine. This is an important step towards developing biomarkers that can serve as indicators of an organism's metabolic state. Another important platform of HMT is the Biomarker Discovery Platform, which specializes in the identification of biomarkers associated with specific diseases. This platform is often used by pharmaceutical companies to develop new drugs tailored to the specific needs of patients with certain diseases. HMT has also developed a comprehensive metabolome database that allows researchers and analysts to compare their own data with a variety of reference data. This database contains information on thousands of metabolites and allows researchers to better understand metabolic pathways and biomolecular interactions. In recent years, HMT has also increased its investment in clinical research to explore the potentials of metabolome analysis in the diagnosis and treatment of cancer, diabetes, cardiovascular diseases, metabolic disorders, and other diseases. In collaboration with clinics and universities, HMT has conducted several clinical studies to evaluate the effectiveness of metabolome analysis in the early detection and monitoring of diseases. HMT is headquartered in Tsuruoka, Japan, and is also active in the US, Europe, and Asia. The company employs over 100 people and has become a leading provider of metabolome analysis and services. In summary, HMT has developed unique expertise in the field of metabolome analysis and is able to offer a wide range of products and services to support researchers and analysts in the study of the metabolic processes of the human body. With a strong emphasis on innovation and clinical research, HMT will continue to play an important role in the development of new diagnostic and therapeutic approaches tailored to the specific needs of patients. Human Metabolome Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Human Metabolome Technologies's Employee Base

Human Metabolome Technologies's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Human Metabolome Technologies's operational capacity and future potential.

Year-to-Year Comparison

Assessing Human Metabolome Technologies's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Human Metabolome Technologies's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Human Metabolome Technologies’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Human Metabolome Technologies stock

How many employees does Human Metabolome Technologies have this year?

Human Metabolome Technologies has 73 undefined employees this year.

How many employees did Human Metabolome Technologies have compared to the previous year?

Compared to the previous year, Human Metabolome Technologies had 0% more employees.

What impact did the number of employees have on the company Human Metabolome Technologies?

The number of employees has a direct impact on the efficiency and productivity of Human Metabolome Technologies. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Human Metabolome Technologies?

The number of employees can also have an impact on investors of Human Metabolome Technologies, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Human Metabolome Technologies affect the company?

An increase in equity of Human Metabolome Technologies can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Human Metabolome Technologies's equity affect the company?

A reduction in equity of Human Metabolome Technologies can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Human Metabolome Technologies?

Some factors that can influence the equity of Human Metabolome Technologies include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Human Metabolome Technologies so important for investors?

The equity of Human Metabolome Technologies is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Human Metabolome Technologies influence the company?

The number of employees at Human Metabolome Technologies can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Human Metabolome Technologies evolved in recent years?

In recent years, the number of employees at Human Metabolome Technologies has changed by 0.

How many employees does Human Metabolome Technologies currently have?

Human Metabolome Technologies currently has 73 undefined employees.

Why is the number of employees important for investors of Human Metabolome Technologies?

The number of employees is important for investors of Human Metabolome Technologies as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Human Metabolome Technologies take to change the number of employees?

To change the number of employees, Human Metabolome Technologies can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Human Metabolome Technologies pay?

Over the past 12 months, Human Metabolome Technologies paid a dividend of 15 JPY . This corresponds to a dividend yield of about 2.46 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 15 JPY.

What is the dividend yield of Human Metabolome Technologies?

The current dividend yield of Human Metabolome Technologies is 2.46 %.

When does Human Metabolome Technologies pay dividends?

Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Human Metabolome Technologies?

Human Metabolome Technologies paid dividends every year for the past 0 years.

What is the dividend of Human Metabolome Technologies?

For the upcoming 12 months, dividends amounting to 15 JPY are expected. This corresponds to a dividend yield of 2.46 %.

In which sector is Human Metabolome Technologies located?

Human Metabolome Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Human Metabolome Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Human Metabolome Technologies pay the last dividend?

The last dividend was paid out on 9/1/2024.

What was the dividend of Human Metabolome Technologies in the year 2023?

In the year 2023, Human Metabolome Technologies distributed 10 JPY as dividends.

In which currency does Human Metabolome Technologies pay out the dividend?

The dividends of Human Metabolome Technologies are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Human Metabolome Technologies

Our stock analysis for Human Metabolome Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Human Metabolome Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.